EHC vs. INSM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EHC and INSM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EHC | INSM |
|---|---|---|
| Company Name | Encompass Health Corporation | Insmed Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 11.51 billion USD | 42.39 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | September 24, 1986 | June 1, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EHC and INSM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EHC | INSM |
|---|---|---|
| 5-Day Price Return | -0.59% | 3.32% |
| 13-Week Price Return | -8.62% | 50.56% |
| 26-Week Price Return | -6.92% | 194.11% |
| 52-Week Price Return | 13.81% | 170.81% |
| Month-to-Date Return | -0.93% | 5.30% |
| Year-to-Date Return | 22.13% | 189.17% |
| 10-Day Avg. Volume | 0.66M | 2.06M |
| 3-Month Avg. Volume | 0.78M | 2.36M |
| 3-Month Volatility | 20.17% | 43.07% |
| Beta | 0.75 | 1.05 |
Profitability
Return on Equity (TTM)
EHC
24.37%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
In the upper quartile for the Health Care Providers & Services industry, EHC’s Return on Equity of 24.37% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
INSM
-183.55%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
INSM has a negative Return on Equity of -183.55%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
EHC
9.33%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
A Net Profit Margin of 9.33% places EHC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
INSM
-264.83%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
INSM has a negative Net Profit Margin of -264.83%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
EHC
17.29%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
An Operating Profit Margin of 17.29% places EHC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
INSM
-258.92%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
INSM has a negative Operating Profit Margin of -258.92%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | EHC | INSM |
|---|---|---|
| Return on Equity (TTM) | 24.37% | -183.55% |
| Return on Assets (TTM) | 8.07% | -54.63% |
| Net Profit Margin (TTM) | 9.33% | -264.83% |
| Operating Profit Margin (TTM) | 17.29% | -258.92% |
| Gross Profit Margin (TTM) | 95.65% | 76.54% |
Financial Strength
Current Ratio (MRQ)
EHC
1.14
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
EHC’s Current Ratio of 1.14 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
INSM
4.63
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
INSM’s Current Ratio of 4.63 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EHC
1.02
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
EHC’s Debt-to-Equity Ratio of 1.02 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
INSM
0.77
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
INSM’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.77. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
EHC
6.58
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
EHC’s Interest Coverage Ratio of 6.58 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
INSM
-27.79
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
INSM has a negative Interest Coverage Ratio of -27.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | EHC | INSM |
|---|---|---|
| Current Ratio (MRQ) | 1.14 | 4.63 |
| Quick Ratio (MRQ) | 0.97 | 4.18 |
| Debt-to-Equity Ratio (MRQ) | 1.02 | 0.77 |
| Interest Coverage Ratio (TTM) | 6.58 | -27.79 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EHC
0.60%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
EHC’s Dividend Yield of 0.60% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
INSM
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EHC
12.77%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
EHC’s Dividend Payout Ratio of 12.77% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
INSM
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | EHC | INSM |
|---|---|---|
| Dividend Yield (TTM) | 0.60% | 0.00% |
| Dividend Payout Ratio (TTM) | 12.77% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EHC
21.43
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
EHC’s P/E Ratio of 21.43 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
INSM
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for INSM is currently unavailable.
Price-to-Sales Ratio (TTM)
EHC
2.00
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
EHC’s P/S Ratio of 2.00 is in the upper echelon for the Health Care Providers & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
INSM
93.64
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
With a P/S Ratio of 93.64, INSM trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
EHC
5.39
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
EHC’s P/B Ratio of 5.39 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
INSM
32.19
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
At 32.19, INSM’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | EHC | INSM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.43 | -- |
| Price-to-Sales Ratio (TTM) | 2.00 | 93.64 |
| Price-to-Book Ratio (MRQ) | 5.39 | 32.19 |
| Price-to-Free Cash Flow Ratio (TTM) | 28.80 | -- |